303 related articles for article (PubMed ID: 27986742)
1. Assessment of the effectiveness and safety of Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain: EDONOT-protocol of a randomised, parallel, controlled, double-blinded and multicentre clinical trial.
Kerckhove N; Mallet C; Pereira B; Chenaf C; Duale C; Dubray C; Eschalier A
BMJ Open; 2016 Dec; 6(12):e013530. PubMed ID: 27986742
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial.
Kerckhove N; Pereira B; Soriot-Thomas S; Alchaar H; Deleens R; Hieng VS; Serra E; Lanteri-Minet M; Arcagni P; Picard P; Lefebvre-Kuntz D; Maindet C; Mick G; Balp L; Lucas C; Creach C; Letellier M; Martinez V; Navez M; Delbrouck D; Kuhn E; Piquet E; Bozzolo E; Brosse C; Lietar B; Marcaillou F; Hamdani A; Leroux-Bromberg N; Perier Y; Vergne-Salle P; Gov C; Delage N; Gillet D; Romettino S; Richard D; Mallet C; Bernard L; Lambert C; Dubray C; Duale C; Eschalier A
Eur J Pain; 2018 Aug; 22(7):1321-1330. PubMed ID: 29577519
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome - IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial.
Kerckhove N; Scanzi J; Pereira B; Ardid D; Dapoigny M
BMJ Open; 2017 Jul; 7(7):e015380. PubMed ID: 28720615
[TBL] [Abstract][Full Text] [Related]
4. Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
Matsuoka H; Ishiki H; Iwase S; Koyama A; Kawaguchi T; Kizawa Y; Morita T; Matsuda Y; Miyaji T; Ariyoshi K; Yamaguchi T
BMJ Open; 2017 Aug; 7(8):e017280. PubMed ID: 28851798
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
6. Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol.
Kaguelidou F; Le Roux E; Mangiarini L; Lundin R; de Leeuw TG; Della Pasqua O; Felisi M; Bonifazi D; Tibboel D; Ceci A; de Wildt SN; Alberti C;
BMJ Open; 2019 Feb; 9(2):e023296. PubMed ID: 30787078
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial-the LENSS study.
de Greef BT; Merkies IS; Geerts M; Faber CG; Hoeijmakers JG
Trials; 2016 Jun; 17(1):306. PubMed ID: 27363506
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy.
Ostenfeld T; Krishen A; Lai RY; Bullman J; Green J; Anand P; Scholz J; Kelly M
Clin J Pain; 2015 Apr; 31(4):283-93. PubMed ID: 25751578
[TBL] [Abstract][Full Text] [Related]
9. Neuropathic Pain Components in Patients with Cancer: Prevalence, Treatment, and Interference with Daily Activities.
Oosterling A; te Boveldt N; Verhagen C; van der Graaf WT; Van Ham M; Van der Drift M; Vissers K; Engels Y
Pain Pract; 2016 Apr; 16(4):413-21. PubMed ID: 25857631
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic Neuropathy.
Soin A; Bock G; Giordano A; Patel C; Drachman D
Pain Physician; 2018 Mar; 21(2):179-190. PubMed ID: 29565948
[TBL] [Abstract][Full Text] [Related]
11. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol.
Matsuoka H; Clark K; Fazekas B; Oyamada S; Brown L; Ishiki H; Matsuda Y; Hasuo H; Ariyoshi K; Lee J; Le B; Allcroft P; Kochovska S; Fujiwara N; Miyaji T; Lovell M; Agar M; Yamaguchi T; Satomi E; Iwase S; Phillips J; Koyama A; Currow DC
BMJ Open; 2022 Feb; 12(2):e050182. PubMed ID: 35131817
[TBL] [Abstract][Full Text] [Related]
12. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.
Ostenfeld T; Krishen A; Lai RY; Bullman J; Baines AJ; Green J; Anand P; Kelly M
Eur J Pain; 2013 Jul; 17(6):844-57. PubMed ID: 23239139
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
Gao Y; Guo X; Han P; Li Q; Yang G; Qu S; Yue L; Wang CN; Skljarevski V; Dueñas H; Raskin J; Gu L
Int J Clin Pract; 2015 Sep; 69(9):957-66. PubMed ID: 25939897
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial.
Attal N; de Andrade DC; Adam F; Ranoux D; Teixeira MJ; Galhardoni R; Raicher I; Üçeyler N; Sommer C; Bouhassira D
Lancet Neurol; 2016 May; 15(6):555-65. PubMed ID: 26947719
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an effectiveness and safety of the electroacupuncture in the management of intractable neuropathic pain: A prospective, open-labeled, randomized, cross-over clinical trial.
Moon JY; Lee CS; Yoo Y; Lee S; Lee SH; Lee S
Medicine (Baltimore); 2020 Dec; 99(51):e23725. PubMed ID: 33371123
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial.
Rullán M; Bulilete O; Leiva A; Soler A; Roca A; González-Bals MJ; Lorente P; Llobera J;
Trials; 2017 Jan; 18(1):24. PubMed ID: 28088231
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study.
Mankowski C; Poole CD; Ernault E; Thomas R; Berni E; Currie CJ; Treadwell C; Calvo JI; Plastira C; Zafeiropoulou E; Odeyemi I
BMC Neurol; 2017 Apr; 17(1):80. PubMed ID: 28431564
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
[TBL] [Abstract][Full Text] [Related]
19. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Rice ASC; Dworkin RH; McCarthy TD; Anand P; Bountra C; McCloud PI; Hill J; Cutter G; Kitson G; Desem N; Raff M;
Lancet; 2014 May; 383(9929):1637-1647. PubMed ID: 24507377
[TBL] [Abstract][Full Text] [Related]
20. Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study.
Saxena AK; Bhardwaj N; Chilkoti GT; Malik A; Thakur GK; Bajaj M; Banerjee A; Banerjee BD; Singal A
Pain Med; 2021 Oct; 22(10):2276-2282. PubMed ID: 34097069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
